top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hNKP46 mice(CB-17 SCID)
Strain Name
CB17/lcr-PrkdcscidNcr1tm1(NCR1)Bcgen/Bcgen 
Common Name  B-hNKP46 mice(CB-17 SCID)
Background CB-17 SCID Catalog number 112259
Aliases  CD335, LY94, NK-p46, NKP46
Protein expression analysis

from clipboard


Strain specific NKP46 expression analysis in wild-type and B-hNKP46 mice(CB-17 SCID) by flow cytometry. Splenocytes were collected from CB-17 SCID (+/+) and homozygous B-hNKP46 mice(CB-17 SCID) (H/H), and analyzed by flow cytometry with species-specific NKP46 antibody. Mouse NKP46 was detectable in wild-type mice. Human NKP46 was exclusively detectable in homozygous B-hNKP46 mice(CB-17 SCID).


Protein expression of NKP46 in spleen


from clipboard


Strain specific NKP46 expression analysis in wild-type and B-hNKP46 mice(CB-17 SCID) by flow cytometry. Splenocytes were collected from CB-17 SCID(+/+) and homozygous B-hNKP46 mice(CB-17 SCID)(H/H) (n=3, 6-week old), and analyzed by flow cytometry with species-specific NKP46 antibody. Mouse NKP46 was detectable in wild-type mice. Human NKP46 was exclusively detectable in homozygous B-hNKP46 mice(CB-17 SCID).

Protein expression of NKP46 in bone marrow

from clipboard


Strain specific NKP46 expression analysis in wild-type and B-hNKP46 mice(CB-17 SCID) by flow cytometry. Bone marrow were collected from CB-17 SCID(+/+) and homozygous B-hNKP46 mice(CB-17 SCID)(H/H) (n=3, 6-week old), and analyzed by flow cytometry with species-specific NKP46 antibody. Mouse NKP46 was detectable in wild-type mice. Human NKP46 was exclusively detectable in homozygous B-hNKP46 mice(CB-17 SCID).

Analysis of leukocytes cell subpopulation in spleen

from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were isolated from female CB-17 SCID and B-hNKP46 mice(CB-17 SCID) (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hNKP46 mice(CB-17 SCID) were similar to those in the CB-17 SCID mice, demonstrating that NKP46 humanized does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SD.

Analysis of leukocytes cell subpopulation in bone marrow

from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Bone marrow cells were isolated from female CB-17 SCID and B-hNKP46 mice(CB-17 SCID) (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hNKP46 mice(CB-17 SCID) were similar to those in the CB-17 SCID mice, demonstrating that NKP46 humanized does not change the overall development, differentiation or distribution of these cell types in bone marrow. Values are expressed as mean ± SD.

Analysis of leukocytes cell subpopulation in blood

from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Blood cells were isolated from female CB-17 SCID and B-hNKP46 mice(CB-17 SCID) (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hNKP46 mice(CB-17 SCID) were similar to those in the CB-17 SCID mice, demonstrating that NKP46 humanized does not change the overall development, differentiation or distribution of these cell types in blood. Values are expressed as mean ± SD.


Protein expression analysis via immunohistochemistry(IHC)


from clipboard


IHC of mouse ileum (upper panel) and spleen (bottom panel)

Image 2. Mouse ileum, huNKP46 IHC, approximately 200x. (2A) CB-17 SCID mouse. Labeling for huNKP46 is limited to nonspecific staining. The superficial epithelium of the mucosa (M) and smooth muscle of the tunica muscularis externa (TM) exhibit light nonspecific blushing. The submucosa (SM) is indicated. (2B) B-hNKP46 mice(CB-17 SCID). Small numbers of scattered round cells in the lamina propria (LP) exhibit moderate to strong membranous to cytoplasmic labeling (black arrows). There is light background nonspecific labeling similar to that in (2A). The mucosa (M), submucosa (SM), and tunica muscularis externa (TM) are indicated. 

Image 4. Mouse spleen, huNKP46 IHC, approximately 200x. (4A) CB-17 SCID mouse. There is light nonspecific background labeling of erythrocytes/ serum in the red pulp. Red pulp (RP) is indicated. (4B) BhNKP46 mice(CB-17 SCID). Moderate to large numbers of scattered round cells exhibit moderate to strong membranous to cytoplasmic labeling (black arrows). Red pulp (RP) is indicated.

Note: This experiment was performed by the client using CB-17 SCID and B-hNKP46 mice(CB-17 SCID). All the other materials were provided by the client.



In vivo efficacy of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID)


from clipboard


Antitumor activity of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46-based Ab inhibited BxPC-3 tumor growth in B-hNKP46 mice(CB-17 SCID). BxPC-3 cells (5E6) were subcutaneously implanted into B-hNKP46 mice(CB-17 SCID) (male, 7-8 week-old, n=4). Mice were grouped when tumor volume reached approximately 150-200 mm3, at which time they were treated with anti-human NKP46-based Ab with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46-based Ab was efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID). Values are expressed as mean ± SEM. (All antibodies were provided by the clients)


In vivo efficacy of anti-human NKP46-based Ab-individual tumor growth curves 


from clipboard


Antitumor activity of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46-based Ab inhibited BxPC-3 tumor growth in B-hNKP46 mice(CB-17 SCID). BxPC-3 cells (provided by a client) (5E6) were subcutaneously implanted into B-hNKP46 mice(CB-17 SCID) (male, 7-8 week-old, n=4). Mice were grouped when tumor volume reached approximately 150-200 mm3, at which time they were treated with anti-human NKP46-based Ab with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46-based Ab was efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID). Values are expressed as mean ± SEM. Note:
Note: This experiment was performed by the client using B-hNKP46 mice(CB-17 SCID). All the other materials were provided by the client.



In vivo efficacy of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID)




from clipboard


Antitumor activity of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46-based Ab inhibited BxPC-3 tumor growth in B-hNKP46 mice(CB-17 SCID). BxPC-3 cells (5E6) were subcutaneously implanted into B-hNKP46 mice(CB-17 SCID) (male, 7-8 week-old, n=6). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with anti-human NKP46-based Ab with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46-based Ab was efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID). Values are expressed as mean ± SEM. (All antibodies were provided by the clients)


In vivo efficacy of anti-human NKP46-based Ab-individual tumor growth curves 


from clipboard


Antitumor activity of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46-based Ab inhibited BxPC-3 tumor growth in B-hNKP46 mice(CB-17 SCID). BxPC-3 cells (provided by a client) (5E6) were subcutaneously implanted into B-hNKP46 mice(CB-17 SCID) (male, 7-8 week-old, n=4). Mice were grouped when tumor volume reached approximately 150-200 mm3, at which time they were treated with anti-human NKP46-based Ab with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46-based Ab was efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID). Values are expressed as mean ± SEM. Note:
Note: This experiment was performed by the client using B-hNKP46 mice(CB-17 SCID). All the other materials were provided by the client.

In vivo efficacy of anti-human NKP46 antibodies

from clipboard


Antitumor activity of anti-human NKP46 antibodies (provided by a client) in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46 antibodies inhibited NCI-N87 tumor growth in B-hNKP46 mice(CB-17 SCID). NCI-N87 cells (provided by a client) were subcutaneously implanted into homozygous B-hNKP46 mice(CB-17 SCID)(female, 7-week-old, n=7). Mice were grouped when tumor volume reached approximately 200-250 mm3, at which time they were intraperitoneally injected with anti-human NKP46 antibodies indicated in panel. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46 antibodies were efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID), demonstrating that the B-hNKP46 mice(CB-17 SCID) provide a powerful preclinical model for in vivo evaluation of anti-human NKP46 antibodies. Values are expressed as mean ± SEM. Significance was determined by two-way ANOVA test.  *P < 0.05, **P < 0.01, ***P < 0.001. The overage of this tumor model is 43%.
Note: This experiment was performed by the client using B-hNKP46 mice(CB-17 SCID). All the other materials were provided by the client.

In vivo efficacy of anti-human NKP46-based Ab-individual tumor growth curves 

from clipboard



Antitumor activity of anti-human NKP46 antibodies (provided by a client) in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46 antibodies inhibited NCI-N87 tumor growth in B-hNKP46 mice(CB-17 SCID). NCI-N87 cells (provided by a client) were subcutaneously implanted into homozygous B-hNKP46 mice(CB-17 SCID)(female, 7-week-old, n=7). Mice were grouped when tumor volume reached approximately 200-250 mm3, at which time they were intraperitoneally injected with anti-human NKP46 antibodies indicated in panel. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46 antibodies were efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID), demonstrating that the B-hNKP46 mice(CB-17 SCID) provide a powerful preclinical model for in vivo evaluation of anti-human NKP46 antibodies. Values are expressed as mean ± SEM. Significance was determined by two-way ANOVA test.  *P < 0.05, **P < 0.01, ***P < 0.001. The overage of this tumor model is 43%.
Note: This experiment was performed by the client using B-hNKP46 mice(CB-17 SCID). All the other materials were provided by the client.